Page 28 - GTM-4-3

Global Translational Medicine Anti-inflammatory therapy in CVD

11. Malick WA, Waksman O, Do R, et al. Clinical trial design for doi: 10.1056/NEJMoa1809798
triglyceride-rich lipoprotein-lowering therapies: JACC focus 23. Tardif JC, Kouz S, Waters D, et al. Efficacy and safety of low-
seminar 3/3. J Am Coll Cardiol. 2023;81(16):1646-1658. dose colchicine after myocardial infarction. N Engl J Med.
doi: 10.1016/j.jacc.2023.02.034 2019;381(26):2497-2505.
12. Ramms B, Patel S, Sun X, et al. Interventional hepatic doi: 10.1056/NEJMoa1912388
apoC III knockdown improves atherosclerotic plaque 24. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory
stability and remodeling by triglyceride lowering. JCI therapy with canakinumab for atherosclerotic disease.
Insight. 2022;7(13):e158414. N Engl J Med. 2017;377(12):1119-1131.
doi: 10.1172/jci.insight.158414 doi: 10.1056/NEJMoa1707914
13. Saklayen MG. The global epidemic of the metabolic 25. Perkovic V, Tuttle K, Sattar N, et al. Design of the ZEUS
syndrome. Curr Hypertens Rep. 2018;20(2):12. trial: Interleukin-6 inhibition with ziltivekimab for
doi: 10.1007/s11906-018-0812-z cardiovascular protection in chronic kidney disease. Kidney
Int Rep. 2025;10(S1):S767.
14. Gariani K, Jornayvaz FR. Pathophysiology of NASH in
endocrine diseases. Endocr Connect. 2021;10(2):R52-R65. doi: 10.1016/j.ekir.2024.11.1354

doi: 10.1530/EC-20-0490 26. Ridker PM, Howard CP, Walter V, et al. Effects of
interleukin-1β inhibition with canakinumab on hemoglobin
15. Wolska A, Yang ZH, Remaley AT. Hypertriglyceridemia: A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen:
New approaches in management and treatment. Curr Opin A phase IIb randomized, placebo-controlled trial. JAMA.
Lipidol. 2020;31(6):331-339.
2012;307(21):2300-2309.
doi: 10.1097/MOL.0000000000000710 doi: 10.1001/jama.2012.5733
16. Jomard A, Osto E. High density lipoproteins: Metabolism, 27. O’Donoghue ML, Glaser R, Cavender MA, et al. Effect
function, and therapeutic potential. Front Cardiovasc Med. of losmapimod on cardiovascular outcomes in patients
2020;7:39. hospitalized with acute myocardial infarction: A randomized
doi: 10.3389/fcvm.2020.00039 clinical trial. JAMA. 2016;315(10):1027-1036.
17. Navab M, Anantharamaiah GM, Fogelman AM. The role of doi: 10.1001/jama.2016.1036
high-density lipoprotein in inflammation. Trends Cardiovasc 28. Vosshenrich CAJ, Di Santo JP. Interleukin signaling. Curr
Med. 2005;15(4):158-161. Biol. 2002;12(22):R760-R763.
doi: 10.1016/j.tcm.2005.05.008 doi: 10.1016/S0960-9822(02)01286-1
18. Woudberg NJ, Pedretti S, Lecour S, et al. Pharmacological 29. Hu X, Li J, Fu M, Zhao X, Wang W. The JAK/STAT signaling
intervention to modulate HDL: What do we target? Front pathway: From bench to clinic. Signal Transduct Target Ther.
Pharmacol. 2018;8:989. 2021;6:402.
doi: 10.3389/fphar.2017.00989 doi: 10.1038/s41392-021-00791-1
19. Kastelein JJP, Hsieh A, Dicklin MR, Ditmarsch M, Davidson 30. Holtmann H, Enninga J, Kälble S, et al. The MAPK
MH. Obicetrapib: Reversing the tide of CETP inhibitor kinase kinase TAK1 plays a central role in coupling the
disappointments. Curr Atheroscler Rep. 2024;26(2):35-44. interleukin-1 receptor to both transcriptional and RNA-
doi: 10.1007/s11883-023-01184-1 targeted mechanisms of gene regulation. J Biol Chem.
2001;276(5):3508-3516.
20. New Amsterdam Pharma. Obicetrapib (TA-8995): A
selective CETP inhibitor for lowering LDL-C. New doi: 10.1074/jbc.M004376200
Amsterdam Pharma. 2025. Available from: https://www. 31. Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in
newamsterdampharma.com/obicetrapibta8995/ [Last inflammation. Signal Transduct Target Ther. 2017;2:e17023.
accessed on 2025 Jan 10].
doi: 10.1038/sigtrans.2017.23
21. Crupi R, Cuzzocrea S. Role of EPA in inflammation:
Mechanisms, effects, and clinical relevance. Biomolecules. 32. Chang SH, Dong C. IL-17F: Regulation, signaling and
2022;12(2):242. function in inflammation. Cytokine. 2009;46(1):7-11.
doi: 10.1016/j.cyto.2008.12.024
doi: 10.3390/biom12020242
22. Ridker PM, Everett BM, Pradhan A, et al. Low-dose 33. Miller AM. Role of IL-33 in inflammation and disease.
methotrexate for the prevention of atherosclerotic events. J Inflamm (Lond). 2011;8(22):22.
N Engl J Med. 2019;380(8):752-762. doi: 10.1186/1476-9255-8-22

Volume 4 Issue 3 (2025) 20 doi: 10.36922/GTM025100024